Free Access
Med Sci (Paris)
Volume 33, Number 11, Novembre 2017
Page(s) 997 - 999
Section Repères
Published online 04 December 2017
  1. Fraumeni JF Jr, Vogel CL, DeVita VT. Familial chronic lymphocytic leukemia. Ann Intern Med 1969 ; 71 : 279–284. [CrossRef] [PubMed] [Google Scholar]
  2. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990 ; 250 : 1233–1238. [Google Scholar]
  3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015 ; 136 : E359–E386. [CrossRef] [PubMed] [Google Scholar]
  4. Albagli O. Protéger et sévir : p53, métabolisme et suppression tumorale. Med Sci (Paris) 2015 ; 31 : 869–880. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Campisi J. Cancer and ageing: rival demons? Nat Rev Cancer 2003 ; 3 : 339–349. [Google Scholar]
  6. Maier B, Gluba W, Bernier B, et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004 ; 18 : 306–319. [CrossRef] [PubMed] [Google Scholar]
  7. Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002 ; 415 : 45–53. [CrossRef] [PubMed] [Google Scholar]
  8. Donehower LA. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol 1996 ; 7 : 269–278. [CrossRef] [PubMed] [Google Scholar]
  9. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, et al. Super p53 mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002 ; 21 : 6225–6235. [CrossRef] [PubMed] [Google Scholar]
  10. Matheu A, Pantoja C, Efeyan A, et al. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev 2004 ; 18 : 2736–2746. [CrossRef] [PubMed] [Google Scholar]
  11. Matheu A, Maraver A, Klatt P, et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007 ; 448 : 375–379. [CrossRef] [PubMed] [Google Scholar]
  12. Carrasco-Garcia E, Arrizabalaga O, Serrano M, et al. Increased gene dosage of Ink4/Arf and p53 delays age-associated central nervous system functional decline. Aging Cell 2015 ; 14 : 710–714. [CrossRef] [PubMed] [Google Scholar]
  13. Threadgill DW. Down’s syndrome: paradox of a tumour repressor. Nature 2008 ; 451 : 21–22. [CrossRef] [PubMed] [Google Scholar]
  14. Sussan TE, Yang A, Li F, et al. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down’s syndrome. Nature 2008 ; 451 : 73–75. [CrossRef] [PubMed] [Google Scholar]
  15. Lane AA, Chapuy B, Lin CY, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet 2014 ; 46 : 618–623. [Google Scholar]
  16. Seluanov A, Hine C, Azpurua J, et al. Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat. Proc Natl Acad Sci USA 2009 ; 106 : 19352–19357. [CrossRef] [PubMed] [Google Scholar]
  17. Tian X, Azpurua J, Ke Z, et al. INK4 locus of the tumor-resistant rodent, the naked mole rat, expresses a functional p15/p16 hybrid isoform. Proc Natl Acad Sci USA 2015 ; 112 : 1053–1058. [CrossRef] [PubMed] [Google Scholar]
  18. Abegglen LM, Caulin AF, Chan A, et al. Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA damage in humans. JAMA 2015 ; 314 : 1850–1860. [CrossRef] [PubMed] [Google Scholar]
  19. Sulak M, Fong L, Mika K, et al. TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants. Elife 2016; 5. [Google Scholar]
  20. Weill JC, Radman M. How good is our genome? Philos Trans R Soc Lond B Biol Sci 2004 ; 359 : 95–98. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.